CompletedPhase 1NCT01943682

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Studying Acute undifferentiated leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Children's Hospital Medical Center, Cincinnati
Principal Investigator: John Perentesis, MD
Children's Hospital Medical Center, Cincinnati
Intervention: CPX-351(drug)
Enrollment: 27 enrolled
Eligibility: 30 years · All sexes
Timeline: 2013 – 2019

Study locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Collaborators

Jazz Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01943682 on ClinicalTrials.gov

Other trials for Acute undifferentiated leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06466395
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
M.D. Anderson Cancer Center

See all trials for Acute undifferentiated leukemia →

← Back to all trials